To test the hypothesis that an inhibitor of G6PDH could further enhance metabolic oxidative stress caused by 2DG (Fig. 1) MDA-MB231 breast cancer cells, PC-3 and DU145 prostate cancer cells were treated with 2DG and/or DHEA for 24 and 48 h followed by clonogenic cell survival assay (Fig. 2). Here, H6PD is linked to prostate cancer.